Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection.
Rupprechter SAE, Sloan DJ, Oosthuyzen W, Bachmann TT, Hill AT, Dhaliwal K, Templeton K, Matovu J, Sekaggya-Wiltshire C, Dear JW. Rupprechter SAE, et al. Br J Clin Pharmacol. 2021 Aug;87(8):3206-3217. doi: 10.1111/bcp.14736. Epub 2021 Jan 26. Br J Clin Pharmacol. 2021. PMID: 33432705 Free PMC article.
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS. Sekaggya-Wiltshire C, et al. Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179. Clin Infect Dis. 2018. PMID: 29514175 Free PMC article. Clinical Trial.
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C. Nabisere R, et al. Trials. 2020 Feb 13;21(1):181. doi: 10.1186/s13063-020-4132-7. Trials. 2020. PMID: 32054536 Free PMC article.
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, Aber F, Alinaitwe L, Nampala J, Najjemba L, Buzibye A, Omali D, Gausi K, Kengo A, Lamorde M, Aarnoutse R, Denti P, Dooley KE, Sloan DJ. Sekaggya-Wiltshire C, et al. Clin Infect Dis. 2023 Feb 8;76(3):e910-e919. doi: 10.1093/cid/ciac585. Clin Infect Dis. 2023. PMID: 35861296 Free PMC article. Clinical Trial.
Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda.
Omali D, Buzibye A, Kwizera R, Byakika-Kibwika P, Namakula R, Matovu J, Mbabazi O, Mande E, Sekaggya-Wiltshire C, Nakanjako D, Gutteck U, McAdam K, Easterbrook P, Kambugu A, Fehr J, Castelnuovo B, Manabe YC, Lamorde M, Mueller D, Merry C. Omali D, et al. Afr J Lab Med. 2023 Feb 7;12(1):1956. doi: 10.4102/ajlm.v12i1.1956. eCollection 2023. Afr J Lab Med. 2023. PMID: 36873289 Free PMC article.
Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
Otaalo B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, Zawedde-Muyanja S, Nampala J, Nanziri C, Alinaitwe L, Aber F, Bayigga J, Nankinga B, Laker E, Owarwo NC, Sabiiti W, Adakun S, Kirenga B, Turyahabwe S, Sloan DJ, Sekaggya-Wiltshire C. Otaalo B, et al. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):481-483. doi: 10.5588/ijtld.23.0010. Int J Tuberc Lung Dis. 2023. PMID: 37231596 No abstract available.
67 results